~~<i id='449B3D7786'><strike id='449B3D7786'><tt id='449B3D7786'><pre id='449B3D7786'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：entertainment 2025-09-27 09:58:41 - browse：9

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Healthy food access boosts outcomes in two studies

knowledge

hotspot

Wikipedia

leisure time

hotspot

AdobeWASHINGTON—DoctorsarestaringdownacuttotheirMedicarepaynextyear,andwhilethenewshasunitedtheminou

WSS

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

How one patient went off dialysis — and others can too

FDA seeks to regulate lab

Paxlovid should be available without a positive Covid test

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Shingles, which affected Dianne Feinstein, is on the rise

knowledge

fashion

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

After a drawn out lobbying fight, ARPA

Activists slam private health insurers over coverage restrictions

Menendez indictment could see pharma lose a key ally

Medicare proposal to cover medical devices draws a mixed reaction

How state and local governments are sidelining science

How to save PrEP access — and even expand it

After a drawn out lobbying fight, ARPA

Dobbs anniversary: the lost opportunity of abortion as health care

FDA seeks to regulate lab

hotspot

NIH chief: government has fallen behind pharma on clinical trials

Publishing genetic code of viruses could cause disaster

Weight loss drugs should be covered by insurers, AMA says

FDA advisers vote against ALS treatment from BrainStorm

Medicare drug price negotiation program allowed for now

FDA advisers vote against ALS treatment from BrainStorm

hotspot

Wikipedia

leisure time

hotspot